Literature DB >> 12612447

Efficient gene transfer to hepatoblastoma cells through asialoglycoprotein receptor and expression under the control of the cyclin A promoter.

Yukihiko Aramaki1, Insugi Lee, Hidetoshi Arima, Takatoshi Sakamoto, Yasushi Magami, Takayuki Yoshimoto, Fuminori Moriyasu, Junichiro Mizuguchi, Yasuhisa Koyanagi, Toshio Nikaido, Seishi Tsuchiya.   

Abstract

Specific gene delivery into hepatoma cells by liposomes and specific gene expression under the control of the cyclin A promoter were examined in HepG2 cells, a hepatoblastoma cell line that overexpresses cyclin A. A plasmid carrying the luciferase gene under the cyclin A promoter sequence was condensed with poly-L-lysine and encapsulated into anionic asialofetuin-labeled liposomes (AF-liposomes), which were preferentially taken up by hepatocytes through the action of the asialoglycoprotein receptor (AgpR). AF-liposomes delivered plasmids to the hepatoma cells by receptor-mediated endocytosis through the AgpR, and transgene expression could be achieved under the control of the cyclin A promoter. Furthermore, a fusogenic lipid, DOPE, as a liposomal component was required for the enhancement of transfection efficiency of AF-liposomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612447     DOI: 10.1248/bpb.26.357

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Optimizing vector application for gene transfer into human hepatoblastoma cells.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Heitmann; Peter Ruck; Guido Seitz; Johannes T Wessels; Marie-Luise Lemken; Ulrich M Lauer; Jörg Fuchs; Michael Bitzer
Journal:  Pediatr Surg Int       Date:  2006-07-29       Impact factor: 1.827

2.  In vitro gene targeting in human hepatoblastoma.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Frank; Heike Buck; Florian Graepler; Marie-Luise Lemken; Heike Heitmann; Guido Seitz; Ulrich M Lauer; Michael Bitzer; Jörg Fuchs
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.